BioSpace News Archive

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has commenced an underwritten public offering of shares of its common stock.

ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of Phil Spencer to its Board of Directors, effective February 9, 2021.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its fourth quarter 2020 financial results after the market closes on Thursday, February 25, 2021.

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the fourth quarter and full year ended December 31, 2020.

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2020.

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2020. Record fourth quarter revenue reflects a strong close to 2020: Revenue of $953 million, an increase of 20% compared to the third quarter of 2020 and $0.5 million higher compared to the prior year period

-Net Product Sales of $1 Billion in 2020, an Increase of 59 Percent Over 2019- -European Medicines Agency’s CHMP Adopted Positive Opinion Recommending Approval of TUKYSA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer-

– Reports Revenues of $1.6 Million Compared with $634,000 in the Year-Ago Period and $314,000 in the Fourth Quarter of Fiscal 2020 – - Leverages EUA-Authorized Assay’s Ability to Discriminate for Certain SARS-CoV-2 Variants to Pursue Market for Genomic Surveillance, Receives Initial Orders –

Ascletis Pharma Inc. announces that Ascletis, through its wholly-owned subsidiary, participates in Sagimet Biosciences Inc.'s US$80 million in crossover financing, led by an undisclosed public equity healthcare investment fund with participation from other existing investors and Rock Springs), along with new investors .

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Qatar Ministry of Public Health has issued an emergency use authorization for COVID-19 Vaccine Moderna.